US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

First Trust SMID Growth Strength ETF

28.82

-0.2257-0.78%

Volume:931.00

Turnover:26.97K

Market Cap:28.82M

PE:- -

High:28.97

Open:28.97

Low:28.82

Close:29.04

Loading ...

Overview Company News Filings

Health Check: New JV for Opyl; Dimerix inks another licensing deal

Dimerix inks agreement for development, commercialisation of kidney disease drug in Japan

The Market Herald

Guess which ASX healthcare stock is up 31% on big news

Closing Bell: ASX stumbles, but Brainchip has mysteriously gained 68pc in five days

Recruitment on track for Dimerix’s global kidney disease trial

Health Check: Telix CEO gets pay bump as company files for US kidney imaging approval

Stocking stuffers: Morgans’ top ASX health picks for 2025

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco

Crucible: Dr Boreham’s A-To-Z of 2024 biotech

LGND: 2025 View Calls for 17% Topline Growth

Zacks Small Cap Research

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/FSGS/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FSGS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","market":"US","secType":"STK","nameCN":"First Trust SMID Growth Strength ETF","latestPrice":28.815,"timestamp":1750190400000,"preClose":29.0407,"halted":0,"volume":931,"delay":0,"floatShares":1000002,"shares":1000002,"eps":0,"marketStatus":"Post-Mkt","change":-0.2257,"latestTime":"06-17 18:22:28 EDT","open":28.97,"high":28.97,"low":28.815,"amount":26967.18,"amplitude":0.005337,"askPrice":43.29,"askSize":200,"bidPrice":14.43,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1750204800000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":29.0407,"sharesOutstanding":1000002,"nav":28.83,"aum":28830057.66,"dividendRate":0.026375,"bidAskSpread":0,"volumeRatio":0.579412},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","floatShares":1000002,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.579412,"shares":1000002,"dividePrice":0.76,"high":28.97,"amplitude":0.005337,"preClose":29.0407,"low":28.815,"week52Low":24.39,"pbRate":"--","week52High":32.96,"institutionHeld":0,"latestPrice":28.815,"eps":0,"divideRate":0.026375,"volume":931,"delay":0,"ttmEps":0,"open":28.97,"prevYearClose":29.7151,"prevWeekClose":28.797,"prevMonthClose":29.1468,"prevQuarterClose":27.34,"fiveDayClose":29.4952,"twentyDayClose":29.83,"sixtyDayClose":27.4162},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FSGS\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2501245496","title":"Health Check: New JV for Opyl; Dimerix inks another licensing deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2501245496","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501245496?lang=en_us&edition=fundamental","pubTime":"2025-01-07 13:00","pubTimestamp":1736226013,"startTime":"0","endTime":"0","summary":"Opyl enters joint venture with X Firm to market its AI-powered TrialKey platform in Europe, Middle East, Africa and North America. Dimerix enters exclusive licence deal with Fuso Pharmaceutical Industries to develop and commercialise DMX-200 to treat FSGS in Japan. Opyl said it would retain its focus on the Asia-Pacific market while leveraging the JV to expand globally.Dimerix inks lucrative licensing deal in JapanDimerix  is continuing its run of licensing deals into 2025 for its ACTION3 phase III drug candidate DMX-200 to treat focal segmental glomerulosclerosis  kidney disease, this time inking a deal with Fuso Pharmaceutical Industries Pty Ltd in Japan.Dimerix said Fuso will be responsible for all development costs, submission and maintenance of the regulatory dossier with the Japanese Pharmaceutical and Medical Device Agency , as well as all sales and marketing activities in Japan.In exchange for these rights Dimerix will receive a 300 million  within 40 days of executing the agre","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/01/1200-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/01/1200-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/health-check-new-jv-for-opyl-dimerix-inks-another-licensing-deal/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["LU0823421333.USD","BK4529","BK4141","UAE","LU2250418816.HKD","LU1989764664.SGD","IE00BMPRXR70.SGD","LU0979878070.USD","LU1064131342.USD","BK4585","IE0004445239.USD","LU0082616367.USD","LU0390134368.USD","LU2054465674.USD","LU0127658192.USD","LU2458330243.SGD","LU1880398471.USD","LU0198837287.USD","LU2458330169.SGD","BK4573","LU1951200564.SGD","GFS","OPT","LU2264538146.SGD","LU0109392836.USD","LU1923623000.USD","LU1988902786.USD","BK4532","BK4566","BK4534","LU0719512351.SGD","BK4512","LU1880398554.USD","BK4588","LU1803068979.SGD","LU0642271901.SGD","LU0823434583.USD","LU0823421416.USD","LU1316542783.SGD","IE0009356076.USD","LU2360106780.USD","BK4554","LU1242518857.USD","BK4139","LU0056508442.USD","FSGS","LU0889565833.HKD","LU1242518931.SGD","LU1951198990.SGD"],"gpt_icon":1},{"id":"2501942072","title":"Dimerix inks agreement for development, commercialisation of kidney disease drug in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2501942072","media":"The Market Herald","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501942072?lang=en_us&edition=fundamental","pubTime":"2025-01-07 07:54","pubTimestamp":1736207640,"startTime":"0","endTime":"0","summary":"Biopharmaceutical company Dimerix Ltd  has partnered with Japanese company FUSO to progress the development and commercialisation of its drug DMX-200 for the treatment of focal segmental glomerulosclerosis  kidney disease.According to the exclusive development and license agreement, FUSO Pharmaceutical Industries Ltd will acquire exclusive rights to develop, register, and commercialise DMX-200 in Japan, taking on all clinical trial costs within the country.The candidate is currently in global Phase 3 clinical development, with a blinded interim analysis expected in August 2025.Dimerix – which retains all commercialisation rights for DMX-200 in all territories otherthan those covered by its agreements with FUSO, Advanz Pharma, and Taiba – will receive up to 10.5 billion  in upfront, development, and sales milestone payments, as well as through royalties.CEO and managing director Dr Nina Webster said Dimerix was pleased to enter this partnership for the development of the candidate in Ja","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/dimerix-inks-agreement-for-development-commercialisation-of-kidney-disease-drug-in-japan-2025-01-07/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7501","FSGS","BK7508","DXB.AU","BK7067"],"gpt_icon":0},{"id":"2501329422","title":"Guess which ASX healthcare stock is up 31% on big news","url":"https://stock-news.laohu8.com/highlight/detail?id=2501329422","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501329422?lang=en_us&edition=fundamental","pubTime":"2025-01-07 07:45","pubTimestamp":1736207112,"startTime":"0","endTime":"0","summary":"Dimerix Ltd  shares are catching the eye of investors on Tuesday. In morning trade, the ASX healthcare stock is up 31% to 46.5 cents. Why is this ASX healthcare stock rocketing?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/07/guess-which-asx-healthcare-stock-is-up-31-on-big-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["DXB.AU","BK7508","BK7501","BK7067","FSGS"],"gpt_icon":0},{"id":"2495956574","title":"Closing Bell: ASX stumbles, but Brainchip has mysteriously gained 68pc in five days","url":"https://stock-news.laohu8.com/highlight/detail?id=2495956574","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495956574?lang=en_us&edition=fundamental","pubTime":"2024-12-30 13:59","pubTimestamp":1735538355,"startTime":"0","endTime":"0","summary":"ASX 200 drops as Santa rally fades Energy and gold stocks rise Brainchip surges another 15pc The ASX 200 had a rough start to the shortened week, sliding 0.36% (as of 4pm) and reversing the much-hyped","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/12/ASX-stumbles-today.-Picture-via-Getty-Images-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/12/ASX-stumbles-today.-Picture-via-Getty-Images-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/news/closing-bell-asx-stumbles-but-brainchip-has-mysteriously-gained-68pc-in-five-days/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["FSGS"],"gpt_icon":0},{"id":"2495557165","title":"Recruitment on track for Dimerix’s global kidney disease trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2495557165","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495557165?lang=en_us&edition=fundamental","pubTime":"2024-12-30 10:50","pubTimestamp":1735527026,"startTime":"0","endTime":"0","summary":"Dimerix recruits Part 2 cohort of patients for ACTION3 global phase III trial. Interim analysis data collection currently scheduled for August 2025. Full recruitment of 286 adult patients expected Q3 CY25. The company’s treatment has orphan drug designation","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/12/DXB-Hero-Pic-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/12/DXB-Hero-Pic-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/recruitment-on-track-for-dimerixs-global-kidney-disease-trial/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["FSGS","ARB"],"gpt_icon":0},{"id":"2495508495","title":"Health Check: Telix CEO gets pay bump as company files for US kidney imaging approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2495508495","media":"Stockheads","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495508495?lang=en_us&edition=fundamental","pubTime":"2024-12-30 09:58","pubTimestamp":1735523900,"startTime":"0","endTime":"0","summary":"Telix has filed for FDA approval of its next key nuclear imaging tool. Dimerix reaches a key recruitment milestone in its phase III kidney disease trial. Proteomics shares bound 20% after endometriosis diagnosis breakthrough","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/12/GettyImages-1295941134-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/12/GettyImages-1295941134-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/health-check-telix-ceo-gets-pay-bump-as-company-files-for-us-kidney-imaging-approval/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4213","TGA","FSGS","PET","BK4192"],"gpt_icon":0},{"id":"2493221534","title":"Stocking stuffers: Morgans’ top ASX health picks for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2493221534","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493221534?lang=en_us&edition=fundamental","pubTime":"2024-12-23 04:45","pubTimestamp":1734900335,"startTime":"0","endTime":"0","summary":"Morgans sees opportunities among several ASX healthcare stocks in 2025. Broker looking at stocks with near-term catalysts or sold down with good entry opportunities. Morgans’ Christmas stocking has mix of up-and-comers alongside mature names","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/12/1200x675-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/12/1200x675-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/stocking-stuffers-morgans-top-asx-health-picks-for-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4585","BK4196","VT","FSGS","PMD","BK4588"],"gpt_icon":0},{"id":"2492838501","title":"ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco","url":"https://stock-news.laohu8.com/highlight/detail?id=2492838501","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492838501?lang=en_us&edition=fundamental","pubTime":"2024-12-18 20:55","pubTimestamp":1734526500,"startTime":"0","endTime":"0","summary":"ZyVersa is advancing a pipeline of first-in-class drug candidates built around two proprietary technologies. - Inflammasome ASC Inhibitor IC 100 designed to attenuate initiation and perpetuation of di","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/18/2998983/0/en/ZyVersa-Therapeutics-CEO-Stephen-C-Glover-to-Attend-JPM-s-Healthcare-Conference-2025-in-San-Francisco.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0215105999.USD","IE00B1XK9C88.USD","LU0170899867.USD","LU2106854487.HKD","LU0048584097.USD","LU1894683264.USD","IE00BDRTCR15.USD","LU0106831901.USD","LU1496350171.SGD","HCSG","SG9999002232.USD","IE0034235188.USD","LU1244550494.USD","LU0203347892.USD","LU0267386448.USD","LU1720051017.SGD","LENZ","IE00BFXG1179.USD","FSGS","LU0417517546.SGD","IE000M9KFDE8.USD","LU1668664300.SGD","LU1670627923.USD","BK4585","IE00B775SV38.USD","LU0211331839.USD","BK4504","BK4550","IE00BZ1G4Q59.USD","BK4139","LU0203345920.USD","LU2552382058.USD","LU0256863811.USD","SG9999002224.SGD","BK4137","BK4207","IE00BDCRKT87.USD","IE00BLSP4239.USD","LU2237443622.USD","BK4516","LU1720051108.HKD","LU2237443978.SGD","LU0211326839.USD","LU1917777945.USD","IE00BHPRN162.USD","IE00BJTD4N35.SGD","IE00BYXW3230.USD","LU0211327993.USD","LU1084165304.USD","LU1032466523.USD"],"gpt_icon":0},{"id":"2492642678","title":"Crucible: Dr Boreham’s A-To-Z of 2024 biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2492642678","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492642678?lang=en_us&edition=fundamental","pubTime":"2024-12-17 04:00","pubTimestamp":1734379202,"startTime":"0","endTime":"0","summary":"From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster.His virtual stethoscope on ha","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/09/boreham-csl-1200_x_675-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/09/boreham-csl-1200_x_675-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/crucible-dr-borehams-a-to-z-of-2024-biotech/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["FSGS"],"gpt_icon":0},{"id":"2491692455","title":"LGND: 2025 View Calls for 17% Topline Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2491692455","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491692455?lang=en_us&edition=fundamental","pubTime":"2024-12-16 17:35","pubTimestamp":1734341700,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals, Inc.  held its annual analyst day on December 10th, 2024 in Boston. The company provided its 2025 expectations calling for topline revenues of $180 to $200 million and core adjusted earnings per share  of $6.00 to $6.25. This represents an approximate 17% increase at the midpoint for revenues and a 9.4% increase in EPS. A slide deck that guides the investor through the presentation is available.Ligand provided a lens into its cash, cash equivalents and revolver credit facility which provides an estimated $345 million in financial capacity to make investments as of September 30, 2024. We anticipate that Ligand can generate another $15 to $20 million in the fourth quarter to increase the amount of firepower to over $360 million. This excludes other sources of capital such as an expansion of the credit facility and equity capital raises that are available through the company’s at-the-market  facility with Stifel, Nicolaus.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/DKiXY5BdjR_uxf.IdRL8Ew--~B/aD0xMjgwO3c9MTkzMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/scr.zacks.com/aa352492d9adb1478ce274c0c128352d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/DKiXY5BdjR_uxf.IdRL8Ew--~B/aD0xMjgwO3c9MTkzMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/scr.zacks.com/aa352492d9adb1478ce274c0c128352d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lgnd-2025-view-calls-17-093500470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0566484027.USD","BK4139","BK4007","FSGS","LU1559883803.SGD","LGND"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":50,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FSGS\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FSGS","amount":0.3931,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"FIRST TRUST EXCHANGE-TRADED FUND VI FIRST TRUST SMID GROWTH STRENGTH ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FSGS\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":0.3931,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FSGS\",market:\"US\",delay:false,,,undefined,":{}}}